Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence and HHT Clinic
The OHSU Dotter Interventional Institute's Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence is a multi-disciplinary center devoted to the evaluation and treatment of patients with HHT. The HHT Center includes physicians who are among the most experienced in evaluating and treating patients with HHT and is one of a group of specialized centers that have been established with the assistance of the HHT Foundation, International. HHT patients in the Pacific Northwest and other regions of the Western United States can enjoy immediate access to a comprehensive HHT care center. Dotter Interventional Institute HHT Center of Excellence has special interest and expertise in the diagnosis and management of pulmonary arteriovenous fistulae and malformations
HHT affects approximately 1 in 5,000 people in the United States. It is a genetic blood vessel disorder characterized by the development of telangiectases, or small arteriovenous malformations (AVMs), which can bleed after only slight trauma. Common symptoms of HHT include bleeding from the nose, mouth, tongue, gastrointestinal tract, lungs, skin, and, less frequently, other organs. Other symptoms of HHT include shortness of breath, fatigue, strokes, transient ischemic attacks (TIAs), brain abscesses, migraine headaches, and chronic anemia. At the Dotter Interventional Institute HHT Center of Excellence, physicians are prepared to evaluate and treat patients with any and all of these problems.
Dr. Mark S. Chesnutt is the director of the Dotter Interventional Institute HHT Center of Excellence. He evaluates all patients with HHT or patients who are suspected of having HHT in the HHT Clinic and coordinates their care.
Mark Chesnutt, M.D.